Case presentation: A 62 year-old female with Parkinson‘s disease underwent Deep Brain Stimulation (DBS) placement in October 2023. The device was turned on after six days from surgery with worsening of dyskinesias leading to withdrawal of antiparkinsonian medications. The patient develops behavioral changes and agitation. There is a new DBS adjustment on the 18th post-operative day (POD) followed by the reintroduction of levodopa in low doses. Fluctuations in the level of consciousness persisted, with the appearance of drowsiness. From the 23rd POD onwards she started tachycardia, hypertensive peaks and hallucinations. Investigation for infectious was negative. The patient develops refractory hyperthermia (41 ºC), worsening tremors, reduced level of consciousness, increased creatinine and CK levels (maximum 7,000U/L), and thrombocytopenia (54,000 U/mm³). The hypothesis of Parkinsonism-hyperthermia syndrome complicated with renal failure due to rhabdomyolysis was raised, medications with dopaminergic blockade were suspended, antiparkinsonian medications were escalated, benzodiazepine was reintroduced, dantrolene was started with good control of tremors and correction of hyperthermia. There was no improvement in the level of consciousness and emergency orotracheal intubation was performed and transfer to the ICU. Over the course of days, the patient was able to walk, eat orally and communicate verbally without cognitive complaints. She was discharged with the DBS system on associated with pharmacological therapy. The patient had been using quetiapine regularly since 2019 due to a psychotic episode. Discussion: Parkinsonism-hyperthermia syndrome is a rare and potentially fatal complication that occurs when antiparkinsonian drugs are abruptly discontinued, and may also occur when the DBS system functions suddenly stops working. Other risk factors include dehydration, infections and use of neuroleptics. Symptoms are similar to neuroleptic malignant syndrome, with dysautonomia, hyperthermia, rigidity or tremors, and rhabdomyolysis classically within 7 days of changing the dopaminergic drug. Complications such as sepsis, respiratory and renal failure and seizures have also been described. Thrombocytopenia is rarely described in these cases and can be explained by the modulatory role played by dopamine in the platelet response. It is crucial to return to doses of dopaminergic drugs prior to the onset of the syndrome and reactivate the DBS system. The use of bromocriptine and/or amantadine during acute management, as well as the use of dantrolene as an adjuvant to control tremor and hyperthermia, are valid therapeutic options. Final comments: The acute worsening of parkinsonian symptoms associated with signs of dysautonomia should raise the suspicion of parkinsonism-hyperthermia syndrome, which may eventually lead to thrombocytopenia. Treatment is based on intensive clinical support, return of medications to usual doses and correction of risk factors.
Read more